Logo
Login
$BDSX
$21.95 +$0.69 (3.25%) Close

Company Executives

$BDSX Management Team

Ms. Robin Cowie

Chief Financial Officer

Treasurer

Secretary

Age 45
Compensation $875.5K USD
Sex Female

Mr. John Patience

Independent Chairman of the Board

Age 77
Compensation $306.4K USD
Sex Male

Mr. Scott Hutton

President

Chief Executive Officer

Director

Age 53
Compensation $2.085M USD
Sex Male

Mr. Kieran O'Kane

Chief Commercial Officer

Age 48
Compensation $900.6K USD
Sex Male

Board of Directors

From the proxy statement filed Apr 9, 2026
Directors
7
serving now
Independent
5 of 5
stated in the proxy; 2 not stated
Average tenure
8.3 years
from year joined
CEO also chairs the board
No
John Patience
Director Age On board Independent Committees Other public boards Pay Source
Jean Franchi
Not stated 2020
6 years
 Not stated
Audit Committee · Chair
VectorY Therapeutics Not stated
Hany Massarany
Not stated 2020
6 years
 Independent
Compensation Committee · Chair
Accelerate Diagnostics Not stated
Jon Faiz Kayyem
Not stated 2021
5 years
 Independent
Compensation Committee
Inhibrix Biosciences, Inc. Not stated
Scott Hutton
CEO
 Not stated 2020
6 years
 Not stated None stated Eximis Surgical, Inc. Paid as CEO
John Patience
Board chair
 Not stated 2008
18 years
 Independent
Compensation Committee
Accelerate Diagnostics, Inc. Not stated
Lawrence T. Kennedy, Jr.
Not stated 2023
3 years
 Independent
Nominating and Corporate Governance Committee
Healthcare for Kids, Caliber Healthcare Solutions, Revolution 4.0, Health Carousel Not stated
Matthew Strobeck
Not stated 2012
14 years
 Independent
Nominating and Corporate Governance Committee · Chair
QuidelOrtho Corporation, Accelerate Diagnostics, Monteris Medical Corporation Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

2 disclosed in the proxy filed Apr 9, 2026
members of our board of directors
members of our board of directors who invested in the consortium
$46.00 per share
2024

Purchase of Series A Preferred Stock in the April 2024 private placement at $46.00 per share

With the Company Open in proxy
Chief Executive Officer, Chief Financial Officer and Chief Commercial Officer
members of the Company's management team, including our Chief Executive Officer, Chief Financial Officer and Chief Commercial Officer
$46.00 per share
2024

Purchase of Series A Preferred Stock in the April 2024 private placement at $46.00 per share

With the Company Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans